Fact: One in 19 people will be diagnosed with colon cancer at some point in their lifetimes. Risk rises with age, and everyone over the age of 50 should be screened. The most common test is a colonoscopy, which rates among the least pleasant mainstream medical procedures.
Sometimes we joke about these invasive exams, but they're no laughing matter. Colon cancer kills a very high percentage of the people it affects, and early detection is key. But the critical clinical advantage of early detection is forfeited if people aren't screened, and studies show only about half the people who need to be screened really are.
An emerging technology has been proven to solve this problem, and that is the virtual colonoscopy. It's a noninvasive test that uses a CT scan from outside the body instead of a scope inside the body.
The most important question, of course, is whether this test is accurate. And the answer will surprise you. Not only is the virtual colonoscopy extremely accurate and effective at detecting colon cancer -- 90% -- it turns out that the traditional optical colonoscopy isn't as failsafe as previously thought. There are a number of places inside the colon where potentially deadly polyps can lurk and where the optical scope has difficulty visualizing them. But there's no hiding from a CT scanner.
Sometimes we joke about these invasive exams, but they're no laughing matter. Colon cancer kills a very high percentage of the people it affects, and early detection is key. But the critical clinical advantage of early detection is forfeited if people aren't screened, and studies show only about half the people who need to be screened really are.
An emerging technology has been proven to solve this problem, and that is the virtual colonoscopy. It's a noninvasive test that uses a CT scan from outside the body instead of a scope inside the body.
The most important question, of course, is whether this test is accurate. And the answer will surprise you. Not only is the virtual colonoscopy extremely accurate and effective at detecting colon cancer -- 90% -- it turns out that the traditional optical colonoscopy isn't as failsafe as previously thought. There are a number of places inside the colon where potentially deadly polyps can lurk and where the optical scope has difficulty visualizing them. But there's no hiding from a CT scanner.
The name of this company is iCAD (Nasdaq: ICAD). And it has several catalysts behind it that make its shares a very compelling investment that offers strong potential returns:
With a pending approval that will open up a new market, a strong balance sheet and existing industry-leading technology, iCAD is poised to deliver outstanding results not only to patients but to investors.
Long-term investors interested in capturing the remarkable returns possible from exploiting a leading technology should dig in for the long-term and a double-digit price target.
More active traders should consider an immediate purchase at under $1.75 with a price target of $2.25 and a stop at $1.50. I anticipate this +28.6% gain in the near term to stem from approval of iCAD's virtual colonoscopy product.
http://www.icadmed.com/
No comments:
Post a Comment